A federal judge has recently given approval for a class action lawsuit to proceed against Galderma Laboratories regarding its Differin acne product. The plaintiff, Skylar Williams, alleges that the product contains benzene, a known carcinogen. Williams asserted that this presence of benzene indicates Galderma’s failure to comply with the Food and Drug Administration’s Good Manufacturing Practices. This alleged non-compliance purportedly resulted in the Differin products being misbranded and adulterated.
The judgement allowing the class action to proceed represents a significant step in holding manufacturers accountable for their production practices and ensuring consumer safety. For more detailed information, you can read the original report here.